ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based,
nutraceutical company devoted to improving the way people age,
announced today three strategic hires to its executive team.
Joining the company are Megan Jordan as Chief
Communications Officer & Senior Vice President of Global
Corporate Affairs, Dr. Andrew Shao as Vice President of Scientific
& Regulatory Affairs, and Alberto Bottene as Senior Vice
President of Sales and Business Development.
“ChromaDex has enjoyed
significant growth but the opportunity for Tru Niagen is
just beginning,” said ChromaDex CEO Rob Fried.
“These accomplished professionals will help
sustain the momentum by raising our brand awareness,
leveraging our deep science, and ensuring regulatory
compliance as we expand into new markets.”
As Chief Communications Officer,
Jordan is a member of the executive leadership team and
reports directly to CEO Rob Fried.
She leads ChromaDex’s communications function
globally, including internal/external communications, public
affairs, executive communications, and public relations.
Jordan has been leading the communications function as a
contractor since February, making it a seamless
transition.
Jordan brings decades of experience to her role,
having led corporate communications for Herbalife Nutrition and
Southern California Edison. Previously as an agency executive with
agencies MSLGroup, Cohn & Wolfe, and Zeno Group, Jordan
launched products and drove brand awareness for clients Nestle,
General Motors, Hilton, Kia and Philips, among others. A graduate
of the University of Southern California (USC), Jordan serves on
the Public Relations Board of Advisors for USC’s Annenberg School
of Communications & Journalism and is a member of the Arthur W.
Page Society.
“I am grateful for the opportunity to lead the
communications for ChromaDex and its flagship product Tru Niagen
which represent a scientific breakthrough that has the potential to
impact the health of people around the world,” said Jordan.
Also joining the Company this week is Dr. Andrew
Shao, Vice President of Scientific & Regulatory Affairs,
reporting directly to ChromaDex Chief Scientific Officer Dr.
Matthew Roberts. Dr. Shao has deep experience
within the industry, having led similar functions for the Council
for Responsible Nutrition, Herbalife Nutrition, and Amway’s
Nutrilite, among others. A graduate of Tufts and Brandeis, he has
published more than 60 articles, and serves on the editorial board
of various peer review publications including The Journal of the
International Society of Sports Nutrition, the Journal of Dietary
Supplements, and Advances in Nutrition.
“I’m truly excited to be joining a dynamic and
passionate group at ChromaDex and look forward to helping them
leverage science to achieve their vision,” said Dr. Shao.
Alberto Bottene joins the company as
Senior Vice President of Sales and Business Development, the
role recently vacated by Will Black who retired from his official
capacity in June but remains a valued consultant.
Bottene is a global executive with over 30 years of domestic
and international business experience in launching,
building and managing new markets in the health, beauty and
supplements space. He was a key driver behind the growth of
Wella AG in Latin America as well as Guthy-Renker’s worldwide
expansion. Fluent in English, Spanish and Portuguese and a graduate
of Thunderbird, The American Graduate School of International
Management, Bottene brings his experience and knowledge of
both domestic and international markets to ChromaDex to help propel
the growth of existing and new markets.
“I am eager to join such an innovative company
that is bringing to market this scientific breakthrough destined to
change how consumers view aging. We are just scratching
the surface of Tru Niagen’s future potential,” said Bottene.
About TRU NIAGEN®:TRU NIAGEN®
is a branded dietary supplement brought to market by key
nicotinamide riboside innovator and patent holder, ChromaDex.
NIAGEN® nicotinamide riboside (NR), also supplied by ChromaDex, is
the sole active ingredient in TRU NIAGEN®. Multiple clinical trials
demonstrate NIAGEN® is proven to boost NAD (nicotinamide adenine
dinucleotide) levels, which decline with age. Only NIAGEN® has
twice been successfully reviewed under FDA's new dietary ingredient
(“NDI”) notification program, and has also been successfully
notified to the FDA as generally recognized as safe (“GRAS”).
About ChromaDex:ChromaDex Corp.
is a science-based integrated nutraceutical company devoted to
improving the way people age. ChromaDex scientists partner with
leading universities and research institutions worldwide to uncover
the full potential of NAD and identify and develop novel,
science-based ingredients. Its flagship ingredient, NIAGEN®
nicotinamide riboside, sold directly to consumers as TRU NIAGEN®,
is backed with clinical and scientific research, as well as
extensive IP protection. TRU NIAGEN® is helping the world AGE
BETTER®. ChromaDex maintains a website at www.chromadex.com to
which ChromaDex regularly posts copies of its press releases as
well as additional and financial information about the Company.
Forward-Looking Statements:This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities and Exchange Act of 1934, as amended.
Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects",
"anticipates", "intends", "estimates", "plans", "potential",
"possible", "probable", "believes", "seeks", "may", "will",
"should", "could" or the negative of such terms or other similar
expressions. Such statements include the quotations from
ChromaDex’s Chief Executive Officer, Chief Communications Officer
& Senior Vice President of Global Corporate Affairs and Vice
President of Scientific & Regulatory Affairs. More
detailed information about ChromaDex and the risk factors that may
affect the realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal year ended
December 31, 2018, ChromaDex's Quarterly Reports on Form 10-Q and
other filings submitted by ChromaDex to the SEC, copies of which
may be obtained from the SEC's website at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
ChromaDex Media Contact:Alex Worsham, Director
of Strategic Partnerships310-388-6706 ext.
689alexw@chromadex.com
ChromaDex Investor Relations Contact:Brianna
Gerber, Senior Director of FP&A and Investor
Relations949-419-0288 ext. 127briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024